Niagen (nicotinamide riboside) / ChromaDex - LARVOL DELTA

Maternal Immune Activation Leads to Mitochondrial Dysfunction and a Social Deficit in Offspring That Is Reversed by Nicotinamide Riboside. (PubMed, Nutrients) - "We demonstrated that nicotinamide riboside, a precursor to NAD+ known to restore ΔΨm, significantly attenuates MIA-induced social interaction deficits. Together, these findings highlight mitochondrial function as a promising therapeutic target for symptoms associated with schizophrenia and support the potential for drug discovery aimed at enhancing mitochondrial health."

IO biomarker • Journal • CNS Disorders • Inflammation • Mental Retardation • Metabolic Disorders • Psychiatry • Schizophrenia • TLR3

Dietary Bioactives in Alzheimer's Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies. (PubMed, Nutrients) - " This critical narrative review examines interventional trials for nine prominent DBs relevant to AD: docosahexaenoic acid (DHA), curcumin, resveratrol, epigallocatechin gallate (EGCG), nicotinamide riboside (NR), tricaprilin, vitamin E (α-tocopherol), cannabinoids, and NIC5-15 (D-pinitol). Future research may benefit from early biomarker-defined populations, optimized formulations, multi-nutrient or dietary approaches, and precision nutrition strategies considering genetic risk and baseline nutrient status. DBs may be better positioned for prevention or early-stage intervention rather than late-stage therapy."

Biomarker • Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • CSF Aβ40

Optimal NAD+ level is a prerequisite for small intestinal secretory cell differentiation (IMMUNOLOGY 2026) - "Appropriate levels of NAD+ during the early phase of IEC differentiation is necessary to generate gut SecCs. This study provides a mechanistic link between cellular metabolic state and SecC proportions in the gut."

IO biomarker • ATOH1 • HES1 • IDO1 • NAMPT • NICD

PANoptosis in Alzheimer's disease: The expanding landscape of programmed cell death mechanisms and therapeutic interventions. (PubMed, Free Radic Biol Med) - "Preclinical studies on compounds like celasterol, magnoflorin, calycosin, and liproxstatin-1, along with clinical trials on the drugs including nicotinamide riboside, barcitinib, dexmeditomidine, and semaglutide, suggest a neuroprotective potential by modulating PANoptotic pathways. This review underscores PANoptosis as a critical pathological mechanism in AD and highlights novel therapeutic avenues aimed at disrupting this cell death program to mitigate AD progression."

Journal • Review • Alzheimer's Disease • CNS Disorders • Dementia • Inflammation • Metabolic Disorders • IGF2BP1 • IRF1 • RIPK1 • STING • ZBP1

SOCS3 suppresses glioblastoma growth via JAK-STAT inhibition and mitochondrial unfolded protein response activation. (PubMed, Cell Div) - "SOCS3 exerts dual tumor-suppressive effects in GBM by inhibiting JAK-STAT signaling and activating mitochondrial stress pathways. These findings provide mechanistic insights into the function of SOCS3 and support its potential as a therapeutic target in GBM by promoting UPRmt-driven apoptosis."

Journal • Brain Cancer • Glioblastoma • Metabolic Disorders • Oncology • Solid Tumor • IL6 • SOCS3

Therapeutic potential of dihydronicotinamide riboside (NRH) on obesity and glucose intolerance in mice. (PubMed, Nat Commun) - "However, NRH mitigates high-fat diet-induced metabolic complications when used as a preventive or as a treatment strategy, including improvements in glucose tolerance, increased hepatic expression of lipid catabolism genes and fat redistribution. These results highlight the potential of NRH as a therapeutic agent, although further studies are needed to optimize its use, as higher doses reveal signs of toxicity."

Journal • Preclinical • Genetic Disorders • Obesity

Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia (clinicaltrials.gov) - P1 | N=50 | Active, not recruiting | Sponsor: Mclean Hospital | Recruiting ➔ Active, not recruiting

Enrollment closed • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • APOE • Aβ42

NOMAD: Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment (clinicaltrials.gov) - P4 | N=144 | Recruiting | Sponsor: Center for Eye Research Australia | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2027 ➔ Mar 2028 | Trial primary completion date: Apr 2027 ➔ Oct 2027

Enrollment open • Trial completion date • Trial primary completion date • Retinal Disorders

NRM on Vascular Perfusion in Healthy Adults (clinicaltrials.gov) - P=N/A | N=200 | Enrolling by invitation | Sponsor: Mayo Clinic | Trial completion date: Sep 2026 ➔ Dec 2026 | Trial primary completion date: Feb 2026 ➔ Sep 2026

Trial completion date • Trial primary completion date • Cardiovascular

NR and Exercise for Blood Pressure (clinicaltrials.gov) - P=N/A | N=112 | Not yet recruiting | Sponsor: ZHANG Jiaqi

New trial • Cardiovascular • Hypertension • EDN1

Effects of NR Supplementation on Metabolic Flexibility in Zone 2 Training (clinicaltrials.gov) - P=N/A | N=16 | Recruiting | Sponsor: ZHANG Jiaqi | Not yet recruiting ➔ Recruiting

Enrollment open

FULMINANT DILATED CARDIOMYOPATHY IN PARS2 MITOCHONDRIAL DISEASE REQUIRING VA-ECMO AND HEART TRANSPLANT (ACC 2026) - "Medical genetics recommended L-proline and nicotinamide riboside supplementation... When unexplained lactic acidosis accompanies shock and severe LV dysfunction in adolescents, consider mitochondrial cardiomyopathy and whole genome testing. Timely escalation to VA-ECMO and OHT was crucial in this case and expanded management expectations of this rare disorder."

Acute Kidney Injury • Cardiomyopathy • Cardiovascular • CNS Disorders • Congestive Heart Failure • Cough • Developmental Disorders • Endocrine Disorders • Heart Failure • Metabolic Disorders • Nephrology • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Thrombosis • Transplantation

NAD Supplementation and Vascular Health in PAD (clinicaltrials.gov) - P1/2 | N=8 | Completed | Sponsor: University of Oklahoma | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Peripheral Arterial Disease

NAD+ controls circadian rhythmicity during cardiac aging. (PubMed, Commun Biol) - "Long-term supplementation with the NAD+ precursor nicotinamide riboside (NR) boosts NAD+ levels, reprograms the diurnal transcriptome, and reverses naturally occurring cardiac enlargement in aged female mice...Finally, we demonstrate that changes to the cardiac transcriptome due to NR treatment partially depend on the activity of SIRT1. These findings reveal an essential role for NAD+ in regulation of the cardiac circadian clock upon aging, which opens up new avenues to counteract age-related cardiac disorders."

Journal • Cardiovascular • Heart Failure • PER2

ExRx in FA: NAD+ and Exercise in FA (clinicaltrials.gov) - P=N/A | N=75 | Completed | Sponsor: Children's Hospital of Philadelphia | Active, not recruiting ➔ Completed | Trial completion date: Feb 2026 ➔ Oct 2025

Trial completion • Trial completion date • Ataxia • Friedreich ataxia • Movement Disorders

SIRT3-mediated deacetylation of FoxM1 prevents pulmonary fibrosis via modulating the activation of pulmonary fibroblasts. (PubMed, Redox Biol) - "Importantly, treatment with nicotinamide riboside was found to suppress the activation of pulmonary fibroblasts and protect mice from bleomycin-induced pulmonary fibrosis by activating SIRT3. These insights suggest potential therapeutic strategies against pulmonary fibrosis, focusing on modulating this pathway for effective treatment. This work opens new avenues for the development of targeted therapies aimed at mitigating the progression of IPF."

Journal • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • FASLG • FOXM1 • SIRT3

The use of NAD, NADH, and NAD Precursors in Parkinson's Disease: A Systematic Review and Meta-analysis (AAN 2026) - "NAD⁺ and its precursors—such as nicotinamide riboside and niacin—may restore mitochondrial bioenergetics and mitigate disease progression.Design/ A systematic review and meta-analysis were done in accordance with PRISMA and Cochrane guidelines... Although statistical significance was not recognized, NAD⁺ and its precursors showed consistent trends toward improved motor outcomes and favorable tolerability in PD. These results support the potential of NAD⁺-based interventions as safe, mitochondria-targeted adjunct therapies and highlight the need for larger, long-term randomized trials to confirm efficacy of the treatment."

Retrospective data • Review • CNS Disorders • Metabolic Disorders • Movement Disorders • Parkinson's Disease

Nicotinamide mononucleotide and nicotinamide riboside attenuate cytokine production in human keratinocytes via suppression of p38 Pathway. (PubMed, Mol Biol Rep) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Axonal protection by nicotinamide riboside with the SIRT1-AMPK pathway in TNF-induced optic nerve damage. (PubMed, Mol Biol Rep) - No abstract available

Journal • Oncology

Nicotinamide Riboside Alleviates Heat Stress-Induced Intestinal Dysfunction by Enhancing Antioxidant Capacity, Restoring Immune Homeostasis, and Modulating Gut Microbiota in a Boar Model. (PubMed, Mol Nutr Food Res) - "Moreover, NR ameliorated HS-induced immune dysfunction and corrected gut microbial dysbiosis. These results suggest the therapeutic potential of NR as a nutritional intervention to mitigate HS-induced intestinal damage."

Journal • Gastrointestinal Disorder • Immune Modulation • Immunology

NRH attenuates age-related hearing loss by suppressing cochlear ferroptosis and cellular senescence via Sirt3 activation. (PubMed, Free Radic Biol Med) - "Our findings demonstrate that NRH mitigates ARHL in C57BL/6 mice, holding significant translational potential for ARHL treatment."

Journal • Otorhinolaryngology • SIRT3

ATF5-mediated mitochondrial UPR inhibited RANKL in Porphyromonas gingivalis LPS-treated osteoblasts. (PubMed, Arch Oral Biol) - "ATF5-mediated UPRmt regulates RANKL expression through mtROS and mitochondrial membrane potential. UPRmt could be a potential target involved in the regulation of bone resorption in periodontitis."

Journal • Dental Disorders • Metabolic Disorders • Periodontitis • ATF5 • TNFRSF11B • TNFSF11

Mitochondrial Resilience in Glaucoma: Targeting NAD+ Metabolism and Oxidative Stress in Retinal Ganglion Cell Degeneration with Nicotinamide Riboside and Berberine: Preliminary Clinical Evidence. (PubMed, Diseases) - "The clinical trends identified in this retrospective cohort have substantiated the translational significance of NR + BBR supplementation as a potential adjunctive approach in glaucoma management. NAD+ repletion and engagement of the AMPK-SIRT-NRF2 pathway may enhance mitochondrial resilience in RGCs. Collectively, these findings offer initial clinical evidence advocating for additional controlled studies on NR + berberine supplementation, while mechanistic interpretations have been derived from the existing literature and are hypothesis-generating."

Journal • CNS Disorders • Glaucoma • Metabolic Disorders • Ophthalmology

Acetylation of PRDX5 aggravates the oxidative stress and apoptosis of retinal neurons induced by ischemia-reperfusion. (PubMed, Tissue Cell) - "The effects of PRDX5 acetylation were analyzed using nicotinamide and nicotinamide riboside chloride (NRC) in the OGD/R model...Our study suggested that PRDX5 plays a vital role in protecting against oxidative stress and apoptosis in retinal I/R injury. The acetylation of PRDX5 inhibits its antioxidant and anti-apoptotic functions."

Journal • Cardiovascular • Glaucoma • Ophthalmology • Reperfusion Injury

Repeated Disuse Atrophy Imprints a Molecular Memory in Skeletal Muscle: Transcriptional Resilience in Young Adults and Susceptibility in Aged Muscle. (PubMed, Adv Sci (Weinh)) - "NMRK2, an NAD+ biosynthesis gene, was the most downregulated gene across both atrophy periods, and supplementation with its substrate, nicotinamide riboside (NR), improved myotube size in MuSCs derived post-atrophy. Overall, repeated disuse atrophy imprints a molecular memory in skeletal muscle shaping transcriptional resilience in young adults and exaggerated susceptibility in aged muscle."

Journal • Muscular Atrophy • CHRNA1 • CHRND • NR4A1 • NR4A3